PE20091426A1 - Compuestos de piridina - Google Patents
Compuestos de piridinaInfo
- Publication number
- PE20091426A1 PE20091426A1 PE2008001987A PE2008001987A PE20091426A1 PE 20091426 A1 PE20091426 A1 PE 20091426A1 PE 2008001987 A PE2008001987 A PE 2008001987A PE 2008001987 A PE2008001987 A PE 2008001987A PE 20091426 A1 PE20091426 A1 PE 20091426A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonamide
- pyridin
- compounds
- methylcarbamoil
- carbamoil
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 abstract 1
- -1 CARBAMOYLAMINO Chemical class 0.000 abstract 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 abstract 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 abstract 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 abstract 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
REFERIDA A COMPUESTOS DERIVADOS DE PIRIDINA DE FORMULA (I), DONDE R1 ES FENILO, TIOFENILO, FURILO, ENTRE OTROS; R2 Y R4 SON CADA UNO HALO, CN, NO2, OH, ENTRE OTROS; R3 Y R5 SON CADA UNO H; R6 Y R7 SON CADA UNO H, ALQUILO, HALOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-CLORO-N-({4-METOXI-6-[(METILCARBAMOIL)AMINO]PIRIDIN-2-IL}-CARBAMOIL)-1-BENZOTIOFENO-2-SULFONAMIDA, N-{[4-BROMO-6-[(CARBAMOILAMINO)PIRIDIN-2-IL]CARBAMOIL}-5-METILTIOFENO-3-SULFONAMIDA, N-{[4-BROMO-6-[(METILCARBAMOIL)AMINO]PIRIDIN-2-IL}CARBAMOIL)-5-METILTIOFENO-3-SULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A SU PROCEDIMIENTO DE PREPARACION Y A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. DICHOS COMPUESTOS SON INHIBIDORES DE FBPasa SIENDO UTILES PARA EL TRATAMIENTO DE DIABETES MELLITUS TIPO I, II O III, DESEQUILIBRIO EN LA TOLERANCIA DE LA GLUCOSA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122017 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091426A1 true PE20091426A1 (es) | 2009-09-23 |
Family
ID=40676394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001987A PE20091426A1 (es) | 2007-11-30 | 2008-11-27 | Compuestos de piridina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8163778B2 (es) |
| EP (1) | EP2227452A2 (es) |
| JP (1) | JP2011504898A (es) |
| KR (1) | KR20100072098A (es) |
| CN (1) | CN102026978A (es) |
| AR (1) | AR069436A1 (es) |
| AU (1) | AU2008328956A1 (es) |
| BR (1) | BRPI0820203A2 (es) |
| CA (1) | CA2706576A1 (es) |
| CL (1) | CL2008003546A1 (es) |
| IL (1) | IL205666A0 (es) |
| MX (1) | MX2010005714A (es) |
| PE (1) | PE20091426A1 (es) |
| TW (1) | TW200922574A (es) |
| WO (1) | WO2009068468A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5689321B2 (ja) * | 2010-01-21 | 2015-03-25 | 石原産業株式会社 | ２−アミノ−４−トリフルオロメチルピリジン類の製造方法 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA025166B1 (ru) | 2012-08-21 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Производные пиридина |
| CN104496895B (zh) * | 2014-12-18 | 2017-02-01 | 天津汉德威药业有限公司 | 一种水解制备异烟酸的方法 |
| CN113527194B (zh) * | 2021-03-15 | 2023-10-03 | 武威广达科技有限公司 | 一种2-氨基-3-氯-5-三氟甲基吡啶的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD9688A (es) * | ||||
| US2977375A (en) * | 1953-02-11 | 1961-03-28 | Boehringer & Soehne Gmbh | Process of manufacturing n-sulphanilyl ureas |
| GB797474A (en) * | 1955-07-20 | 1958-07-02 | Boehringer & Soehne Gmbh | Sulphonylurea derivatives |
| DE1011413B (de) * | 1955-11-28 | 1957-07-04 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung von oral wirksamen Antidiabetika |
| US4293330A (en) * | 1979-10-09 | 1981-10-06 | E. I. Du Pont De Nemours And Company | Herbicidal N-(pyridinylaminocarbonyl)benzenesulfonamides |
| CA2058198A1 (en) * | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
| AUPN193095A0 (en) * | 1995-03-24 | 1995-04-27 | Polychip Pharmaceuticals Pty Ltd | Potassium ion channel blockers |
| US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU784370B2 (en) * | 1999-12-22 | 2006-03-23 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| TW200409643A (en) | 2002-07-23 | 2004-06-16 | Sankyo Co | Preventive agents for diabetes mellitus |
| FR2889190A1 (fr) * | 2005-08-01 | 2007-02-02 | Merck Sante Soc Par Actions Si | Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant |
| TW200738245A (en) * | 2005-08-22 | 2007-10-16 | Sankyo Co | Pharmaceutical composition containing FBPase inhibitor |
| DK200600313A (da) * | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
-
2008
- 2008-11-20 WO PCT/EP2008/065911 patent/WO2009068468A2/en not_active Ceased
- 2008-11-20 KR KR1020107011716A patent/KR20100072098A/ko not_active Abandoned
- 2008-11-20 AU AU2008328956A patent/AU2008328956A1/en not_active Abandoned
- 2008-11-20 JP JP2010535337A patent/JP2011504898A/ja active Pending
- 2008-11-20 CN CN2008801184645A patent/CN102026978A/zh active Pending
- 2008-11-20 MX MX2010005714A patent/MX2010005714A/es not_active Application Discontinuation
- 2008-11-20 CA CA2706576A patent/CA2706576A1/en not_active Abandoned
- 2008-11-20 BR BRPI0820203-6A patent/BRPI0820203A2/pt not_active IP Right Cessation
- 2008-11-20 EP EP08853903A patent/EP2227452A2/en not_active Withdrawn
- 2008-11-24 US US12/276,440 patent/US8163778B2/en not_active Expired - Fee Related
- 2008-11-27 AR ARP080105162A patent/AR069436A1/es unknown
- 2008-11-27 TW TW097146046A patent/TW200922574A/zh unknown
- 2008-11-27 PE PE2008001987A patent/PE20091426A1/es not_active Application Discontinuation
- 2008-11-28 CL CL2008003546A patent/CL2008003546A1/es unknown
-
2010
- 2010-05-10 IL IL205666A patent/IL205666A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009068468A2 (en) | 2009-06-04 |
| CL2008003546A1 (es) | 2010-02-05 |
| KR20100072098A (ko) | 2010-06-29 |
| TW200922574A (en) | 2009-06-01 |
| EP2227452A2 (en) | 2010-09-15 |
| US8163778B2 (en) | 2012-04-24 |
| CA2706576A1 (en) | 2009-06-04 |
| JP2011504898A (ja) | 2011-02-17 |
| MX2010005714A (es) | 2010-07-01 |
| IL205666A0 (en) | 2010-11-30 |
| AR069436A1 (es) | 2010-01-20 |
| AU2008328956A1 (en) | 2009-06-04 |
| US20090143439A1 (en) | 2009-06-04 |
| CN102026978A (zh) | 2011-04-20 |
| BRPI0820203A2 (pt) | 2015-06-16 |
| WO2009068468A3 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091426A1 (es) | Compuestos de piridina | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| DK2203430T3 (da) | N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV) | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| CO6160235A2 (es) | Isoxazolinas insecticidas | |
| PE20120691A1 (es) | Derivados de n1-sulfonil-5-fluoropirimidinona | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| EA201170772A1 (ru) | Органические соединения | |
| MA32727B1 (fr) | Pyrazolylaminopyridines au titre d'inhibiteurs de fak | |
| DE602007009420D1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| ATE517885T1 (de) | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs | |
| ECSP099330A (es) | Compuesto de indol | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| PE20091843A1 (es) | Inhibidores de catepsina c | |
| UY30050A1 (es) | Derivados de pirimido-oxazinil-fenilo, sales de los mismos, composiciones, preparaciones y aplicaciones | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| CU20090048A7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2008003472A1 (es) | Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias. | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| PE20120688A1 (es) | Derivados de n1-acil-5-fluoropirimidinona | |
| PE20070097A1 (es) | Agonistas del receptor de niacina y composiciones que contienen tales compuestos | |
| PE20080675A1 (es) | DERIVADOS DE SULFONAMIDA COMO INHIBIDORES DE LA FRUCTOSA-1,6-BISFOSFATASA (FBPasa) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |